Zai Lab receives FDA Fast Track designation for DLL3-targeting ADC zocilurtatug pelitecan (Zoci) in extrapulmonary neuroendocrine carcinomas (epNECs)
https://finviz.com/quote?t=ZLAB&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.